Please use this identifier to cite or link to this item: https://doi.org/10.1038/mt.2013.242
DC FieldValue
dc.titleAdoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma
dc.contributor.authorChia, W.-K.
dc.contributor.authorTeo, M.
dc.contributor.authorWang, W.-W.
dc.contributor.authorLee, B.
dc.contributor.authorAng, S.-F.
dc.contributor.authorTai, W.-M.
dc.contributor.authorChee, C.-L.
dc.contributor.authorNg, J.
dc.contributor.authorKan, R.
dc.contributor.authorLim, W.-T.
dc.contributor.authorTan, S.-H.
dc.contributor.authorOng, W.-S.
dc.contributor.authorCheung, Y.-B.
dc.contributor.authorTan, E.-H.
dc.contributor.authorConnolly, J.E.
dc.contributor.authorGottschalk, S.
dc.contributor.authorToh, H.-C.
dc.date.accessioned2014-11-26T09:03:35Z
dc.date.available2014-11-26T09:03:35Z
dc.date.issued2014-01
dc.identifier.citationChia, W.-K., Teo, M., Wang, W.-W., Lee, B., Ang, S.-F., Tai, W.-M., Chee, C.-L., Ng, J., Kan, R., Lim, W.-T., Tan, S.-H., Ong, W.-S., Cheung, Y.-B., Tan, E.-H., Connolly, J.E., Gottschalk, S., Toh, H.-C. (2014-01). Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Molecular Therapy 22 (1) : 132-139. ScholarBank@NUS Repository. https://doi.org/10.1038/mt.2013.242
dc.identifier.issn15250016
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/110486
dc.description.abstractThe outcomes for patients with metastatic or locally recurrent Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) remain poor. Adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes (EBV-CTLs) has proven clinical efficacy, but it has never been evaluated in the first-line treatment setting in combination with chemotherapy. To evaluate the safety and efficacy of a chemotherapy in combination with adoptive EBV-CTL transfer, we conducted a phase 2 clinical trial consisting of four cycles of gemcitabine and carboplatin (GC) followed by up to six doses of EBV-CTL. Thirty-eight patients were enrolled, and 35 received GC and EBV-CTL. GC-CTL therapy resulted in a response rate of 71.4% with 3 complete responses and 22 partial responses. With a median follow up of 29.9 months, the 2-year and 3-year overall survival (OS) rate was 62.9 and 37.1%, respectively. Five patients did not require further chemotherapy for more than 34 months since initiation of CTL. Infusion of CTL products containing T cells specific for LMP2 positively correlated with OS (hazard ratio: 0.35; 95% confidence interval: 0.14-0.84; P = 0.014). Our study achieved one of the best survival outcomes in patients with advanced NPC, setting the stage for a future randomized study of chemotherapy with and without EBV-CTL. © The American Society of Gene & Cell Therapy.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1038/mt.2013.242
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.description.doi10.1038/mt.2013.242
dc.description.sourcetitleMolecular Therapy
dc.description.volume22
dc.description.issue1
dc.description.page132-139
dc.description.codenMTOHC
dc.identifier.isiut000329213500016
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

128
checked on Nov 23, 2020

WEB OF SCIENCETM
Citations

119
checked on Nov 23, 2020

Page view(s)

119
checked on Nov 21, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.